PT - JOURNAL ARTICLE AU - Kedar Kirtane AU - Hany Elmariah AU - Christine H Chung AU - Daniel Abate-Daga TI - Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead AID - 10.1136/jitc-2021-002723 DP - 2021 Jul 01 TA - Journal for ImmunoTherapy of Cancer PG - e002723 VI - 9 IP - 7 4099 - http://jitc.bmj.com/content/9/7/e002723.short 4100 - http://jitc.bmj.com/content/9/7/e002723.full SO - J Immunother Cancer2021 Jul 01; 9 AB - While immune checkpoint inhibitors (ICIs) have ushered in major changes in standards of care for many solid tumor malignancies, primary and acquired resistance is common. Insufficient antitumor T cells, inadequate function of these cells, and impaired formation of memory T cells all contribute to resistance mechanisms to ICI. Adoptive cellular therapy (ACT) is a form of immunotherapy that is rapidly growing in clinical investigation and has the potential to overcome these limitations by its ability to augment the number, specificity, and reactivity of T cells against tumor tissue. ACT has revolutionized the treatment of hematologic malignancies, though the use of ACT in solid tumor malignancies is still in its early stages. There are currently three major modalities of ACT: tumor-infiltrating lymphocytes (TILs), genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T cells. TIL therapy involves expansion of a heterogeneous population of endogenous T cells found in a harvested tumor, while TCRs and CAR T cells involve expansion of a genetically engineered T-cell directed toward specific antigen targets. In this review, we explore the potential of ACT as a treatment modality against solid tumors, discuss their advantages and limitations against solid tumor malignancies, discuss the promising therapies under active investigation, and examine future directions for this rapidly growing field.